Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

SEC Form 8-K: Other Events

BPTH_8-K_20241125

SEC Form 8-K: Press Release dated November 15, 2024

BPTH20241115_8-K

SEC Form 10-Q: For Period ending September 30, 2024

BPTH_20241114_10-Q

SEC ARS: Annual Report 2023

BPTH_20241024_ARS

SEC Form DEFA-14A: Additional Proxy Materials

BPTH_20241025_DEFA14A

SEC DEF-14A: Proxy Statement

BPTH_20241025_DEF_14A

SEC Form 424b3 Prospectus – October 23, 2024

BPTH._424B3_20241023

SEC Form 14A: Preliminary Proxy Statement

BPTH_PRE_14A

SEC Form 8-K: Press Release dated October 10, 2024

BPTH_20241010_8-K_EDGAR

SEC For 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

BPTH__20240913_8-K

Bio-Path Holdings

All Rights Reserved

Office:

625 Stanwix Street
Pittsburgh, PA, 15222

T: (630) 708-0750

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us